HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- HOOKIPA Pharma announced the sale of its immuno-oncology assets, primarily HB-200 and HB-700 development programs, to NeoTrail Therapeutics for an undisclosed amount. - HB-200 (eseba-vec) is an investigational immunotherapy for HPV16 positive cancers that showed positive preliminary Phase 2 data in head and neck cancer patients. - HB-700 represents a novel arenaviral immunotherapy targeting multiple KRAS mutations in lung, colorectal, and pancreatic cancers, with Phase 1 readiness achieved. - The transaction, signed January 28, 2026, is expected to close in Q2 2026 and ensures continued clinical development of these promising cancer therapeutics.
- BioNTech's BNT113, an mRNA cancer vaccine targeting HPV16+ oncoproteins E6 and E7, is being evaluated in the Phase 2 AHEAD-MERIT trial combined with pembrolizumab versus pembrolizumab alone for unresectable recurrent or metastatic HPV+ head and neck squamous cell carcinoma. - The vaccine demonstrated potent antigen-specific T cell responses in the investigator-initiated Phase 1/2 HARE-40 basket trial in patients with HPV16+ cancers. - Cue Biopharma's CUE-101, a targeted IL-2-based immunotherapy, has shown clinical activity and favorable tolerability as monotherapy in Phase 1 trials for HPV16+ recurrent/metastatic head and neck squamous cell carcinoma. - The HPV+ recurrent/metastatic head and neck cancer pipeline includes over 5 active companies developing targeted therapies, with multiple promising candidates advancing through clinical development.
• HOOKIPA Pharma has completed enrollment in its Phase 1b clinical trial evaluating HB-500 for HIV treatment, marking a key milestone in the program. • The trial includes 30 participants across five U.S. sites and assesses the safety, tolerability, reactogenicity, and immunogenicity of HB-500 in HIV patients. • HB-500, developed in collaboration with Gilead Sciences, is a therapeutic vaccine designed to induce robust and durable immunity for a potential HIV cure. • Primary completion of the Phase 1b trial is expected in the second half of 2025, with Gilead having the option to further develop the program.
• HOOKIPA Pharma's HB-200 (eseba-vec) demonstrates encouraging results in clinical trials for HPV16-positive head and neck cancers, addressing a significant unmet medical need. • A pivotal Phase 2/3 trial (AVALON-1) is slated to begin in Q4 2024, evaluating HB-200 in combination with Keytruda for first-line treatment, with initial results expected in 2026. • HOOKIPA's arenavirus platform extends beyond HB-200, with candidates like HB-700 and HB-500 advancing, and a partnership with Gilead Sciences for HB-400. • Analysts highlight HB-200's potential to capture a significant portion of the head and neck cancer market if efficacy surpasses historical data.
